/
Neurology
Neurofibromatosis 1
4
Pipeline Programs↗
10
Active Trials↗
3
Companies Involved↗
Neurofibromatosis 1 is an early-stage landscape with 4 programs across 3 companies. The most active players are AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
12
clinical trials
Recruiting7 · 58%
Active, not recruiting2 · 17%
Enrolling by invitation1 · 8%
Completed1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
12 trials
Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden
Enrolling by invitation·AAnn & Robert H Lurie Children's Hospital of Chicago·N/A·NCT05238909·200 enrolled
Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II
Terminated·—·Phase 2·NCT02728388·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)